Information Provided By:
Fly News Breaks for February 5, 2020
MNTA
Feb 5, 2020 | 05:10 EDT
Piper Sandler analyst Danielle Brill raised her price target for Momenta Pharmaceuticals (MNTA) to $45 from $35 to reflect increased probability of success for M254 following last month's positive preliminary immune thrombocytopenic purpura data. The analyst thinks ITP could be a greater than $2B market for M254 and she keeps an Overweight rating on Momenta shares.
News For MNTA From the Last 2 Days
There are no results for your query MNTA